BioLife Solutions, Inc. announced that the Hart-Scott-Rodino antitrust waiting period for its proposed acquisition by Repligen Corporation expired on September 3, 2026. Under the merger agreement, BioLife shareholders will receive $11.25 in cash and 0.1442 shares of Repligen common stock per share. The transaction remains subject to customary closing conditions, including approval by BioLife's stockholders at a special meeting scheduled for October 5, 2026. BioLife Solutions operates in the biotechnology industry, providing cell therapy solutions and services.
